|
Stan Watowich, PhD, Founder & CEO
Dr. Watowich is inventor of Ridgeline Therapeutics' technology, upon which he founded the company. He serves as the company's CEO to help with the launch and capitalization of the company. Additionally, he is Associate Professor of Biochemistry & Molecular Biology at the University of Texas Medical Branch and recent director of the University of Texas (UT) System's state-wide entrepreneurship program developed in partnership with UT McCombs School of Business. He is an accomplished educator, researcher, serial inventor, entrepreneur, and developer of innovative world-class resources. |
|
Harshini Neelakantan, PhD, Executive Director for Research & Development
Dr. Neelakantan is a co-inventor of Ridgeline Therapeutics' founding technology, an established pharmaceutical scientist with 9+ years of experience in hit-to-lead, translational in vivo validation, and preclinical therapeutics development for varied disease indications, including metabolic (obesity), neurological (acute and chronic pain), neuropsychiatric (addiction sciences), and muscular diseases. Dr. Neelakantan is experienced with commercialization plan development and NIH SBIR proposal development. |
|
Neil Warma, MBA, Executive Chair
Neil Warma is a successful healthcare entrepreneur having founded, managed and advised numerous biotech and pharmaceutical companies across the globe over the past 25 yrs. Previously, as President and CEO of Opexa Therapeutics (NASDAQ:OPXA), he led the turnaround and rebuilding of the company’s cell therapy platform and oversaw its advance through clinical development in autoimmune and orphan diseases, expansion into China and its eventual merger with Acer Therapeutics (NASDAQ:ACER). He has been CEO of Viron Therapeutics and Head of Global Pharma Policy and Advocacy at Novartis Pharmaceuticals (Basel, Switzerland). |
|
Business Advisory Board
|
|
The Business Advisory Board is comprised of leading Houston-area senior executives and early-stage investors with highly successful records at moving therapeutic biotech companies to clinical trials, IPOs, and/or exit deals.
|
|
Darrell Carney, PhD
CEO & President, Chrysalis BioTherapeutics Philip Speros, PhD, MBA
Chief Operating Officer, Aggredyne |
